1	Quimioterapia	quimioterapia	NCFS000	C0392920#C0013216#C3665472	régimen/tratamiento#procedimiento	0-13	657_ANS_clinical_caseMIR	SENT1	B-Grp_Medicamento	-
2	basada	basar	VMP00SF	-	-	14-20	657_ANS_clinical_caseMIR	SENT1	-	-
3	en	en	SPS00	C1720294#C0332285	calificador#atributo	21-23	657_ANS_clinical_caseMIR	SENT1	-	-
4	antraciclinas	antraciclinas	NCFP000	-	-	24-37	657_ANS_clinical_caseMIR	SENT1	B-Grp_Medicamento	-
5	y	y	CC	C1706368	calificador	38-39	657_ANS_clinical_caseMIR	SENT1	-	-
6	taxanos	taxanos	NC00AO0	-	-	40-47	657_ANS_clinical_caseMIR	SENT1	B-Grp_Medicamento	-
7	,	,	Fc	-	-	47-48	657_ANS_clinical_caseMIR	SENT1	-	-
8	radioterapia	radioterapia	NCFS000	C1522449	-	49-61	657_ANS_clinical_caseMIR	SENT1	B-Grp_Medicamento	-
9	y	y	CC	C1706368	calificador	62-63	657_ANS_clinical_caseMIR	SENT1	-	-
10	trastuzumab	trastuzumab	NC00SC0	C0728747	sustancia#producto	64-75	657_ANS_clinical_caseMIR	SENT1	B-Grp_Medicamento	-
11	.	.	Fp	-	-	75-76	657_ANS_clinical_caseMIR	SENT1	-	-

1	Quimioterapia	quimioterapia	NCFS000	C0392920#C0013216#C3665472	régimen/tratamiento#procedimiento	0-13	657_ANS_clinical_caseMIR	SENT2	B-Grp_Medicamento	-
2	basada	basar	VMP00SF	-	-	14-20	657_ANS_clinical_caseMIR	SENT2	-	-
3	en	en	SPS00	C1720294#C0332285	calificador#atributo	21-23	657_ANS_clinical_caseMIR	SENT2	-	-
4	antraciclinas	antraciclinas	NCFP000	-	-	24-37	657_ANS_clinical_caseMIR	SENT2	B-Grp_Medicamento	-
5	y	y	CC	C1706368	calificador	38-39	657_ANS_clinical_caseMIR	SENT2	-	-
6	taxanos	taxanos	NC00AO0	-	-	40-47	657_ANS_clinical_caseMIR	SENT2	B-Grp_Medicamento	-
7	,	,	Fc	-	-	47-48	657_ANS_clinical_caseMIR	SENT2	-	-
8	radioterapia	radioterapia	NCFS000	C1522449	-	49-61	657_ANS_clinical_caseMIR	SENT2	B-Grp_Medicamento	-
9	y	y	CC	C1706368	calificador	62-63	657_ANS_clinical_caseMIR	SENT2	-	-
10	tamoxifeno	tamoxifeno	NC00SC0	C0039286	producto#sustancia	64-74	657_ANS_clinical_caseMIR	SENT2	B-Grp_Medicamento	-
11	.	.	Fp	-	-	74-75	657_ANS_clinical_caseMIR	SENT2	-	-

1	Quimioterapia	quimioterapia	NCFS000	C0392920#C0013216#C3665472	régimen/tratamiento#procedimiento	0-13	657_ANS_clinical_caseMIR	SENT3	B-Grp_Medicamento	-
2	basada	basar	VMP00SF	-	-	14-20	657_ANS_clinical_caseMIR	SENT3	-	-
3	en	en	SPS00	C1720294#C0332285	calificador#atributo	21-23	657_ANS_clinical_caseMIR	SENT3	-	-
4	antraciclinas	antraciclinas	NCFP000	-	-	24-37	657_ANS_clinical_caseMIR	SENT3	B-Grp_Medicamento	-
5	y	y	CC	C1706368	calificador	38-39	657_ANS_clinical_caseMIR	SENT3	-	-
6	taxanos	taxanos	NC00AO0	-	-	40-47	657_ANS_clinical_caseMIR	SENT3	B-Grp_Medicamento	-
7	,	,	Fc	-	-	47-48	657_ANS_clinical_caseMIR	SENT3	-	-
8	y	y	CC	C1706368	calificador	49-50	657_ANS_clinical_caseMIR	SENT3	-	-
9	radioterapia	radioterapia	NCFS000	C1522449	-	51-63	657_ANS_clinical_caseMIR	SENT3	B-Grp_Medicamento	-
10	.	.	Fp	-	-	63-64	657_ANS_clinical_caseMIR	SENT3	-	-

1	Quimioterapia	quimioterapia	NCFS000	C0392920#C0013216#C3665472	régimen/tratamiento#procedimiento	0-13	657_ANS_clinical_caseMIR	SENT4	B-Grp_Medicamento	-
2	basada	basar	VMP00SF	-	-	14-20	657_ANS_clinical_caseMIR	SENT4	-	-
3	en	en	SPS00	C1720294#C0332285	calificador#atributo	21-23	657_ANS_clinical_caseMIR	SENT4	-	-
4	antraciclinas	antraciclinas	NCFP000	-	-	24-37	657_ANS_clinical_caseMIR	SENT4	B-Grp_Medicamento	-
5	y	y	CC	C1706368	calificador	38-39	657_ANS_clinical_caseMIR	SENT4	-	-
6	taxanos	taxanos	NC00AO0	-	-	40-47	657_ANS_clinical_caseMIR	SENT4	B-Grp_Medicamento	-
7	,	,	Fc	-	-	47-48	657_ANS_clinical_caseMIR	SENT4	-	-
8	radioterapia	radioterapia	NCFS000	C1522449	-	49-61	657_ANS_clinical_caseMIR	SENT4	B-Grp_Medicamento	-
9	e	y	CC	C1706368	calificador	62-63	657_ANS_clinical_caseMIR	SENT4	-	-
10	inhibidores	inhibidor	NCMP000	-	-	64-75	657_ANS_clinical_caseMIR	SENT4	B-Grp_Medicamento	-
11	de	de	SPS00	C0332285	atributo	76-78	657_ANS_clinical_caseMIR	SENT4	I-Grp_Medicamento	-
12	la	el	DA0FS0	-	-	79-81	657_ANS_clinical_caseMIR	SENT4	I-Grp_Medicamento	-
13	aromatasa	aromatasa	NCFS000	-	-	82-91	657_ANS_clinical_caseMIR	SENT4	I-Grp_Medicamento	-
14	,	,	Fc	-	-	91-92	657_ANS_clinical_caseMIR	SENT4	-	-
15	dado	dar	VMP00SM	C1947971	calificador	93-97	657_ANS_clinical_caseMIR	SENT4	-	-
16	que	que	PR0CN000	-	-	98-101	657_ANS_clinical_caseMIR	SENT4	-	-
17	es	ser	VSIP3S0	-	-	102-104	657_ANS_clinical_caseMIR	SENT4	-	-
18	postmenopáusica	postmenopáusico	AQ0FS0	-	-	105-120	657_ANS_clinical_caseMIR	SENT4	-	-
19	.	.	Fp	-	-	120-121	657_ANS_clinical_caseMIR	SENT4	-	-

